Newswise — New York, NY (June 8, 2021) - Mount Sinai Innovation Partners (MSIP), the commercialization engine of the Mount Sinai Health System (Mount Sinai) in New York City, has launched Elementa Labs, a virtual incubator program that aims to position health care and biotechnology startup companies for the next stage in their development.
The program empowers companies to strategically align with Mount Sinai, gaining access to subject matter experts in health care and the potential to advance their core technology platforms. Participating companies will work directly with a Mount Sinai champion who will facilitate navigation within the Health System and enable access to key stakeholders, resources, and know-how to advance product development.
“Elementa Labs will integrate Mount Sinai’s research and clinical expertise with the business and product development infrastructure of health care startup companies,” said Erik Lium, PhD, President of MSIP and Chief Commercial Innovation Officer of Mount Sinai Health System. “We look forward to engaging with entrepreneurs to bring health care innovations to the patient population.”
The first member of Elementa’s inaugural cohort is digital health company avoMD, which has launched a next-generation platform providing decision support for clinicians. The company will work with Mount Sinai to create a strategic path to conduct research, further validate studies, and surface the depth of clinical needs for their platform at a leading health care system.
“We are thrilled by the opportunity to enhance our platform and offerings by working with Mount Sinai, a global leader in education, cutting-edge research and innovation, and high-quality care,” said Laurence Coman, Chief Operating Officer and Co-Founder of avoMD. “Elementa Labs will help take avoMD to the next level.”
Companies interested in applying can visit the Elementa Labs web page for more information. For the first cohort, the rolling application process concludes on Thursday, September 30, 2021.
About Mount Sinai Innovation Partners (MSIP)
Mount Sinai Innovation Partners (MSIP) is responsible for driving the real-world application and commercialization of Mount Sinai discoveries and inventions, and the development of research partnerships with industry. Our aim is to translate discoveries and inventions into healthcare products and services that benefit patients and society. MSIP is accountable for the full spectrum of commercialization activities required to bring Mount Sinai inventions to life. These activities include evaluating, patenting, marketing and licensing new technologies building research, collaborations and partnerships with commercial and nonprofit entities, material transfer and confidentiality, coaching innovators to advance commercially relevant translational discoveries, and actively fostering an ecosystem of entrepreneurship within the Mount Sinai research and health system communities. For more information, please visit www.ip.mountsinai.org or find MSIP on LinkedIn, Twitter, Facebook, Medium, and YouTube.
About the Mount Sinai Health System
The Mount Sinai Health System is New York City's largest academic medical system, encompassing eight hospitals, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. Mount Sinai is a national and international source of unrivaled education, translational research and discovery, and collaborative clinical leadership ensuring that we deliver the highest quality care—from prevention to treatment of the most serious and complex human diseases. The Health System includes more than 7,200 physicians and features a robust and continually expanding network of multispecialty services, including more than 400 ambulatory practice locations throughout the five boroughs of New York City, Westchester, and Long Island. The Mount Sinai Hospital is ranked No. 14 on U.S. News & World Report's "Honor Roll" of the Top 20 Best Hospitals in the country and the Icahn School of Medicine as one of the Top 20 Best Medical Schools in country. Mount Sinai Health System hospitals are consistently ranked regionally by specialty and our physicians in the top 1% of all physicians nationally by U.S. News & World Report.
avoMD is building the next-gen platform for interactive clinical guidelines and decision support. Leading provider organizations use avoMD to digitize their clinical workflows and algorithms and put them in the hands of all of their providers instantly. The technology functions on a standalone basis via web and mobile apps, or can integrate into the EHR. In usability trials and live deployments, the software has been shown to dramatically increase clinical guideline usability and usage. Led by a team of physicians and informaticians from Harvard, Yale and Mount Sinai, avoMD has over 10 current hospital and urgent care partners including Children’s Minnesota, PM Pediatrics, and Samsung Medical Center.